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Context:Reproductivehormones are incompletely characterizedduring themenopause transition
(MT).
Hypothesis: Increased anovulation and decreased progesterone accompany progress through the
MT.
Design: TheDaily Hormone Study (DHS) of the Study ofWomen’s HealthAcross theNation (SWAN)
included 848women aged 43–53 yr at baselinewho collected daily urine for one cycle or up to 50 d
annually for 3 yr.
Main OutcomeMeasures: LH, FSH, estrone conjugates, and pregnanediol glucuronide levels were
assessed.Cycleswere classifiedbypresumed luteal (ovulatory) statusandbleeding.Hormoneswere
related to time in study, age, menopausal status, and selected variables.
Results:Ovulatory-appearing cycles declined from80.9%atbaseline to 64.7%by the third assessment
(H3). Cycles presumed anovulatory and not ending with bleeding by 50 d (anovulatory/nonbleeding)
increasedfrom8.4 to24%byH3andwereassociatedwithprogress toearlyperimenopause [odds ratio
(OR)  2.66; confidence interval (CI)  1.17–6.04] or late perimenopause (OR  56.21; CI  18.79–
168.12; P 0.0001), African-American ethnicity (OR 1.91; CI 1.06–3.43), and less than high school
education(OR3.51;CI1.62–7.62).Anovulatorycyclesendingwithbleedingremainedatabout10%
frombaselinetoH3;comparedwithovulatorycycles, theywereassociatedwithobesity (OR4.68;CI
1.33–16.52)andmore thanhigh schooleducation (OR2.12;CI1.22–3.69;P0.02). Serumestradiol
in both the highest and lowest categories was associated with anovulatory/nonbleeding collections.
Pregnanediol glucuronide decreased 6.6% for each year on study. Insulin sensitivitymeasures did not
relate strongly to menstrual cycle hormones.
Conclusions:Anovulation without bleeding represents progression of theMT. A small but detect-
able decrease in luteal progesterone excretion occurs as women progress through the MT. (J Clin
Endocrinol Metab 93: 1711–1721, 2008)
Yearly (1) or biannual (2) changes in circulating reproductivehormones (3, 4) have shown decreased estradiol and in-
creased FSH (5) as women traverse the menopause. Because the
FSH rise is observed before an appreciable decline in estradiol, it
has been hypothesized (6) and subsequently demonstrated (7)
that the earliest hormonal change as women enter the meno-
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pausal transition (MT) is reduced inhibin B.Most previous stud-
ies have lacked the ability to focus on the entire menstrual cycle.
Limiting sampling to the follicular phase of the menstrual cycle,
partial cycle sampling, and random sampling, although practi-
cal, does not provide a complete assessment of the dynamics of
the reproductive axis.
Knowledge of the normal patterns of hormone secretion and
excretion across the menstrual cycle of women during the MT
may help refine the probability of fertility as menstrual cyclicity
changes with reproductive aging. Changes in cycle patterns may
assist in predicting the timing of the final menstrual period
(FMP). Finally, the ability to identify reproductive hormonal
disorders concurrent with reproductive aging would be greatly
assisted by defining the ranges and limits of normal menstrual
function.
We hypothesized that luteal function would decrease with
increasing progress through the MT and sought to evaluate
whichother featurespreviously linked to reproductivehormones
in the Study of Women’s Health Across the Nation (SWAN),
such as body size (8), metabolic syndrome (9), and other socio-
demographic variables suchas ethnicity (10,11),wereassociated
with this decline in luteal function. The SWAN Daily Hormone
Study (DHS) included 848 women in the first collection period
who provided daily, first-morning voided urine samples from
menses to menses or up to 50 d (whichever came first). We now
report longitudinal results from the first 3 yr of DHS collection.
Although only a small proportion of women had attained their
FMP by the time of the third DHS collection, we further sought
to identify cycle or hormone changes associated with proximity
to the FMP.
Subjects and Methods
The design of SWAN, amultiethnic cohort study ofmiddle-agedwomen
from seven U.S. communities (12), and details of the specimen collection
protocols have been published (13). Briefly, the DHS is a SWAN sub-
study inwhich a subset of women (n 848 at baseline, orH1 collection)
collect first morning voided urine samples daily for one complete men-
strual cycle or 50 d (whichever comes first) once a year. FSH, LH, estrone
conjugate (E1c), and pregnanediol glucuronide (Pdg) were measured in
the daily urine samples, using validated methodologies that have been
described in detail and prospectively established to allow for objective
assessments of menstrual cycles in perimenopausal women (8, 13). Ob-
jective, validated algorithms were applied to detect hormonal patterns
consistent with folliculogenesis, ovulation, and corpus luteum function.
Participant population and protocol
A volunteer subset of women from all SWAN clinical sites enrolled
in the DHS after recruitment of the main cohort, as previously described
(8, 13–16). This study was approved by all participating sites’ Institu-
tional Review Boards, and written informed consent was obtained from
each participant.
Evaluation of cycles
LH, FSH, E1c, and Pdg levels were measured using previously de-
scribed and validated chemiluminescent assays (8). Data were normal-
ized for creatinine (Cr) concentration. To detect luteal function, we em-
ployed and further validated an objective algorithm developed by
Kassam et al. (17, 18) for use in older reproductive-aged women (8, 13).
Cycles with no evidence of luteal activity were presumed anovulatory
andwere further subdivided into those inwhich the collection ended due
to the onset of a bleeding episode or those in which the collection was
automatically terminated at 50 d without bleeding. For the combined
analysis, data from cycles from the first (H1), second (H2), and third
(H3) DHS collections were used.
Metabolic markers and metabolic syndrome definition
Serum insulin was measured using a previously described RIA (9).
Metabolic syndrome was characterized by three or more of the follow-
ing: 1) abdominal obesity (waist circumference 80 cm for Chinese and
Japanese, 88 cm for Caucasians, African-Americans, and Hispanics);
2) hypertriglyceridemia (fasting triglycerides 150mg/dl); 3) high-den-
sity lipoprotein cholesterol less than 50 mg/dl; 4) high blood pressure
(systolic bloodpressure130mmHg,diastolic bloodpressure85mm
Hg, or on anti-hypertensivemedication); and 5) impaired fasting glucose
or diabetes (fasting glucose  110 mg/dl or on insulin therapy). These
definitions are adapted from two existing sets of criteria, one from the
National Cholesterol Education Program (16) and the other from the
WorldHealthOrganization (21), and have been used in previous SWAN
analyses (9). -Cell function and insulin resistance were derived from
fasting insulin and glucose, using homeostasis model assessment (22).
Data analysis
The analytic sample at the H1–H3 visits were summarized using
frequency distributions for categorical variables [ethnicity, menopausal
status, categorical body mass index (BMI), smoking status (current vs.
past/never), educational level, presence/absence of metabolic syndrome,
and presence/absence of diabetes] andmeans and SD for continuous vari-
ables (age and physical activity) with log transformation when appro-
priate (log glucose, log insulin, log -cell function, and log insulin resis-
tance). Physical activity was assessed from questions adapted from the
Kaiser Physical Activity Survey, based on the Baecke physical activity
questionnaire regarding activity in household and caregiving, sports and
exercise, and daily routine (23–25).
Multivariate models for presumed ovulatory vs. anovulatory collec-
tions and for whole-cycle integrated hormones included as predictors
nonhormonal variables that were hypothesized to relate to cycle char-
acteristics, i.e. ethnicity, baseline age and time since baseline, baseline
and concurrentmenopause status, collection length in days, baseline and
concurrent BMI, smoking, education, and physical activity, as well as
other hormonal (metabolic) exposures hypothesized to be related to
menstrual cycle hormones. To identify factors distinguishing ovulatory
from anovulatory collections, we estimated multivariate random-effects
logistic regression models (26), using PROC GLIMMIX in SAS to ac-
count for within-woman correlation. Anovulatory cycles with andwith-
out (50-d collections) associated bleeding differed in their hormonal
characteristics, as estimated from random-effects linear regression (27).
We therefore compared each anovulatory subgroup to the ovulatory
cycles in a separate logistic regression.
Log-transformed whole-cycle integrated urinary hormones were ad-
justed for the length of the collection and modeled using random-effects
linear regression (27), using PROC MIXED in SAS to handle within-
woman correlation. Model predictors included those from the logistic
regressions as well as baseline ovulatory/bleeding status. From these
models, we estimated adjustedmean integrated hormones for subgroups
defined by concurrent ovulatory/bleeding status, baseline age and time
on study, ethnicity, and baseline metabolic syndrome status.
Observations with missing covariate data were omitted from the
analytic sample. Collections that did not begin with menstrual bleeding
were classified into one of the three cycle categories when possible: ovu-
latory, anovulatorywithbleeding, or anovulatorywithout bleeding. Sep-
arate algorithms were generated to assess whether these cycles fit the
three-category classification appropriately. Results are depicted as
mean  SD.
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Results
Characteristics of the sample
At baseline, reflecting study design, approximately 40% of
participants were Chinese or Japanese, and about 75% were
early perimenopausal (Table 1). Approximately 50%had a BMI
of 25 kg/m2 or less, and only 10% were current smokers. Mean
age increased by approximately a year between consecutive vis-
its; mean BMI also increased. The percentage of perimenopausal
observations rose aswell, as didmean collection length, whereas
the percentage of ovulatory collections declined. At H1, of 834
women providing interpretable hormone data, 26 (3.1%) were
missing covariate data. Comparable numbers at H2 were 700
and 39 (5.6%), and at H3, 624 and 36 (5.8%), respectively.
Attrition between H1 and H2 was 16.1%, and between H2 and
H3 was 27.7%, and was related to having an anovulatory col-
lection at H1, being early perimenopausal at H1, a longer H1
collection, or having a lower educational level. At H1, 27.0% of
the participants were premenopausal (i.e.without menstrual cy-
cle changes that defined them as having entered theMT), but by
theH3 collection, only 13.3%were premenopausal (P 0.0001
for change over time). By entry criteria, no women who contrib-
uted data at H1 had entered the late MT, but by the H3 collec-
tion, 9.5% of women had.
Associations with change in cycle type over time
The proportion of ovulatory cycles progressively decreased
over time, constituting 80.9% of cycles at H1 and declined to
64.7%of cycles byH3. Anovulatory collections that ended in an
episodeofbleedingwithin50dwere relatively stable, about10%
of the sample,whereas the proportion of anovulatory collections
that did not end with a bleeding episode by 50 d nearly tripled,
increasing from 8.4% of cycles at H1 to 24% of cycles at H3.
Obesity was associated with an increased probability of an
anovulatory cycle that ended with a bleed [odds ratio (OR) 
4.68; 95% confidence interval (CI) 1.33–16.52); P 0.02]. A
greater than high school education was also associated with an
increased probability of an anovulatory/bleeding collection
(OR  2.12; CI  1.22–3.69; P  0.02; Table 2).
Not surprisingly, an increased OR of having an anovulatory/
nonbleeding cycle was strongly associated with self-reported
menstrual cycle changes at the annual interview, leading to clas-
sification as early (OR  2.66; CI  1.17–6.04) or late (OR 
56.21; CI  18.79–168.12) perimenopause (P  0.0001). No
such associationwas observed for anovulatory cycles that ended
with a bleed. Older baseline age and longer time on study were
significantly positively related to both anovulatory bleeding
(OR 1.21; CI 1.12–1.31; P 0.0001, andOR 1.17; CI
0.97–1.43;P0.11, respectively) and anovulatory/nonbleeding
TABLE 1. Characteristics of analytic sample at each DHS visit
% (n) or mean (SD)
H1 (n  834) H2 (n  700) H3 (n  624)
Ethnicity
African-American 21.0 (175) 21.3 (149) 20.0 (125)
Caucasian 30.6 (255) 30.0 (210) 29.3 (183)
Chinese 18.1 (151) 18.9 (132) 19.6 (122)
Hispanic 10.0 (83) 8.7 (61) 8.0 (50)
Japanese 20.4 (170) 21.1 (148) 23.1 (144)
Age (yr) 47.3 (2.5) 48.4 (2.5) 49.3 (2.5)
Menopause status
Pre 27.0 (225) 19.3 (135) 13.3 (83)
Early peri 73.0 (609) 73.6 (515) 72.9 (455)
Late peri 0.0 (0) 6.6 (46) 9.5 (59)
Post 0.0 (0) 0.6 (4) 4.3 (27)
Concurrent BMI
Normal/underweight 45.4 (379) 43.7 (306) 43.6 (272)
Overweight 26.9 (224) 26.4 (185) 26.0 (162)
Obese 27.7 (231) 29.9 (209) 30.5 (190)
Current smoking at baseline
No 89.8 (749) 89.0 (623) 89.9 (561)
Yes 10.2 (85) 11.0 (77) 10.1 (63)
Educational level
Less than High school 8.0 (67) 7.9 (55) 7.1 (44)
High school 18.2 (152) 16.7 (117) 16.5 (103)
Some college 30.3 (253) 32.1 (225) 31.6 (197)
Completed college 22.8 (190) 22.9 (160) 24.0 (150)
Postgraduate 20.6 (172) 20.4 (143) 20.8 (130)
Routine physical activity at baseline 2.4 (0.8) 2.4 (0.8) 2.4 (0.8)
Collection length (d) 29.6 (8.4) 32.0 (10.4) 32.9 (11.0)
Presumed ovulatory status
Ovulatory 80.9 (675) 72.1 (505) 64.7 (404)
Anovulatory cycle ending with bleeding 10.7 (89) 10.6 (74) 11.2 (70)
Anovulatory/nonbleeding 8.4 (70) 17.3 (121) 24.0 (150)
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collections (OR 1.51; CI 1.40–1.63;P 0.0001, andOR
1.74; CI 1.44–2.11; P 0.0001, respectively) compared with
presumed ovulatory collections. Both short (21 d) and long
(36 d) collections were significantly associated with anovula-
tory cycles that ended with a bleed compared with ovulatory
cycles (OR  10.56; CI  6.31–17.78, and OR  4.00; CI 
2.64–6.05; P  0.0001). African-American race was the only
ethnicity associated with a higher probability of having an
anovulatory/nonbleeding collection (OR  1.91; CI  1.06–
3.43). Women with less than a high school education were also
considerably more likely to experience an anovulatory/non-
bleeding cycle at theH3 collection (OR3.51;CI1.62–7.62).
Association with changes in whole-cycle hormones
Adjusted mean integrated FSH was significantly increased in
both types of anovulatory cycles (741.31 mIU/mg Cr in cycles
ending with bleeding vs. 864.44 mIU/mg Cr in cycles with no
bleeding) compared with ovulatory cycles (555.43 mIU/mg Cr,
P 0.0001; Fig. 1) andwas higher in cycles that did not endwith
a bleed comparedwith those that did (P 0.04; Fig. 2). Adjusted
meanLHincreasedprogressively fromovulatory (77.61mIU/mg
Cr) to anovulatory cycles with bleeding (87.59 mIU/mg Cr) to
anovulatory/nonbleeding collections (110.04 mIU/mg Cr, P 
0.0001). Adjusted mean whole-cycle E1c was similar between
ovulatory and anovulatory cycles ending with a bleed (1393.94
TABLE 2. Adjusted ORs from multivariate random-effects logistic regression for anovulatory cycles ending with and without a
bleed vs. ovulatory cycles before adding glucose metabolism and annual hormone variables as predictors
Predictor
OR (CI)
Anovulatory cycles ending with a
bleed vs. ovulatory cycles (1817
observations/802 women)
Anovulatory/nonbleeding collections vs.
ovulatory cycles (1925 observations/
831 women)
Ethnicity
Caucasian Reference Reference
African-American 1.08 (0.61–1.92) 1.91 (1.06–3.43)a
Chinese 1.66 (0.76–3.62) 0.68 (0.32–1.46)
Hispanic 2.13 (0.96–4.72) 1.50 (0.62–3.59)
Japanese 1.02 (0.48–2.19) 0.62 (0.29–1.31)
Overall P value 0.17 0.19
Concurrent menopause status
Pre Reference Reference
Early peri 0.96 (0.42–2.23) 2.66 (1.17–6.04)a
Late peri/post 0.78 (0.17–3.71) 56.21 (18.79–168.12)a
Overall P value 0.95 0.0001
Concurrent BMI
Normal/underweight Reference Reference
Overweight 1.37 (0.57–3.32) 1.41 (0.61–3.21)
Obese 4.68 (1.33–16.52)a 2.66 (0.77–9.20)
Overall P value 0.02 0.29
Baseline smoking
No Reference Reference
Yes 0.98 (0.54–1.78) 1.10 (0.60–2.02)
P value 0.94 0.76
H1 age (1-yr difference) 1.21 (1.12–1.31)a 1.51 (1.40–1.63)a
P value 0.0001 0.0001
Time since H1 (1-yr aging) 1.17 (0.97–1.43) 1.74 (1.44–2.11)a
P value 0.11 0.0001
Baseline routine physical activity (1 unit difference) 0.93 (0.73–1.19) 1.12 (0.88–1.43)
P value 0.55 0.36
Educational level
Less than high school 1.47 (0.67–3.20) 3.51 (1.62–7.62)a
High school Reference Reference
More than high school 2.12 (1.22–3.69)a 1.74 (0.98–3.09)
Completed college 1.10 (0.60–2.03) 1.16 (0.61–2.19)
Graduate work 1.23 (0.65–2.33) 1.68 (0.89–3.16)
Overall P value 0.02 0.01
Collection length
21 d 10.59 (6.31–17.78)
22–35 d Reference
36 d 4.00 (2.64–6.05)
Overall P value 0.0001
All ORs were adjusted for all other predictors in table as well as for region (East Coast/Mid-Atlantic, Midwest, West Coast), H1 baseline menopause status, and H1
categorized BMI.
a P value for pairwise comparison with reference group  0.05.
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vs.1333.46g/mgCr) butwas greatly decreased in anovulatory/
nonbleeding collections (848.27 g/mg Cr, P  0.0001). Mean
Pdg was, by definition, markedly lower in both types of anovu-
latory cycles (17.85g/mgCr for cycles endingwith a bleed, and
18.76 g/mg Cr for ones that did not) compared with ovulatory
cycles (51.25 g/mg Cr).
For all collections, baseline age and time in study were asso-
ciated with change in whole-cycle integrated hormones (Fig. 3;
data shown for ovulatory cycles only). For ovulatory cycles, FSH
increased by an estimated 4.4% per year of baseline age and by
3.7% with each additional year on study. Pdg decreased signif-
icantly by 2.6% for each additional year of baseline age and by
5.4% with each additional year on study. LH was not signifi-
cantly related to either baseline age (an increaseof 0.9%per year,
P0.35) or time on study (decrease of 0.7%per year,P0.58).
E1c decreased by 1.4% per year on study (P 0.05) but did not
vary by baseline age. Relationshipswere similarwhen both types
of anovulatory cycles were added to the ovulatory ones.
Ethnicity and whole-cycle hormones
Among ovulatory cycles, integrated LH (P  0.52) and Pdg
(P 0.97) were similar across all ethnic groups. However, FSH
was significantly greater in Chinese- and Japanese-American
women compared with Caucasian women (P 0.03 and 0.009,
respectively), and E1c was significantly lower (P  0.0001) in
Chinese-, Japanese-, and African-American women compared
with Caucasians and Hispanic women. These relationships can
be appreciated in Fig. 4.
Relationship between serum hormones and cycle types
We estimated associations of annual serum hormone concen-
trations with cycle type, again adjusting for participant charac-
teristics in Table 2, and for day of menstrual cycle at the annual
visit’s blood draw. Serum estradiol at the SWAN baseline ex-
amination has been strongly associated with time to the final
menstrual period (28). We therefore tested the association of
estradiol at baseline with cycle type by dividing estradiol into
quintiles, ranging from less than 25 pg/ml (6.9 nmol/ml) to 100
pg/ml or higher (27.8 nmol/ml). As seen in Fig. 5, estradiol ex-
hibited a curvilinear association with anovulatory collections
that did not endwith a bleed but notwith those that did endwith
a bleed. Both the lowest and the highest baseline estradiol cat-
egories were more likely to be anovulatory/nonbleeding collec-
tions thanovulatory cycles comparedwith the reference category
FIG. 1. Adjusted mean whole-cycle urinary reproductive hormones by cycle type. The indicated relationship and statistical significance level for each
hormone are shown in the upper portion of each panel.
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of 50–74.9 pg/ml. Interestingly, categorized estradiol from the
concurrent core visit was not significantly related to cycle type
after adjustment for other factors.
Relationship of metabolic markers to daily hormones
We examined associations of core baseline insulin sensitivity
indicators with cycle type, adjusting for participant character-
istics in Table 2 and omitting women with prevalent diabetes at
the core baseline measurement (Table 3). With the exception of
(log-transformed) -cell function, which was marginally associ-
ated with an increased probability of an anovulatory/nonbleed-
ing collection vs. an ovulatory collection (OR  1.33; CI 
0.99–1.78; P 0.06), insulin sensitivity indicators were overall
not associated with cycle type.
Mean whole-cycle hormones also were compared in women
with and without metabolic syndrome at the core baseline visit,
after adjusting for participant characteristics in Table 2,with the
exception of H1 and concurrent BMI, because BMI is highly
related to waist circumference, a component of the metabolic
syndrome, as well as collection length and cycle type. As can be
seen in Fig. 4, in the subset of ovulatory cycles, FSH, LH, andPdg
were significantly greater in women with the metabolic syn-
drome,whereasE1cwas lower inChinese andhigher inHispanic
women with metabolic syndrome.
Discussion
A number of investigators have attempted to address the dy-
namics of reproductive hormone production across the men-
strual cycle of perimenopausal women. Many of these experi-
mental designs didnot use daily sampling, anddurationsof study
from as short as one cycle to as many as 18 months have been
used to attempt to provide both cross-sectional and longitudinal
data.Metcalf et al.observed evidence of declining luteal function
by decade of life (29) and in associationwith cycle irregularity in
women in their 40s (30). In another study of 50 cycles of women
over age 40, a variety of cycle types were categorized using
weekly urine sampling (31), and a tendency for anovulatory cy-
cles to be observed more frequently as women’s cycles departed
more from normal premenopausal patterns was also observed.
These studies used weekly sampling to determine Pdg excretion,
FIG. 2. Mean daily patterns of FSH, LH, Pdg, and E1c in cycles without luteal function. F, Anovulatory cycles ending with a bleed; E,
anovulatory/nonbleeding collections. Anovulatory collections that did not end with a bleed were terminated at 50 d.
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an interval that might be insufficient to detect ovulatory Pdg
patterns, especially if luteal phases are shorter in perimenopausal
women. Others have noted reduced luteal Pdg (32) and luteal
inhibinA (33–35) inolder reproductive-agedwomen,usingdaily
urinary and serum sampling, respectively. In the FREEDOM
Study, daily urinary hormones were observed in a cohort of 34
women for periods of time from6–18months (36). In this study,
reduced Pdg was associated with higher E1c excretion. On the
other hand, Landgren et al. (37) examined hormones collected
three times per week for 4 wk on an annual basis in a cohort of
13 women who were followed from 4–9 yr up to their FMP.
Although the proportion of anovulatory cycles increased with
progress to menopause, an increase in cycles with low luteal
progesterone production was not reported. Another study of
cycles of women in their 40s did not observe reduced luteal pro-
gesterone secretion (38).
Our findings confirm a small but detectable decrease in Pdg
excretion in apparently ovulatory cycles in serial collections
taken 1 yr apart. Thus, our longitudinal data, taken froma larger
sample thanprevious studies, support thenotion thatprogressive
luteal dysfunction is a characteristic of the MT.
The decrease in luteal Pdg we observed with each year of
participation in the DHS is small, although statistically and per-
haps biologically significant, because it may help explain the
decreased cycle fecundity in women of advanced reproductive
age. Reduced luteal function may be due to a primary defect of
the corpus luteum; however, existing models of cycle changes in
association with the menopause transition favor the hypothesis
that reduced luteal function is an end result of impaired follicu-
logenesis (39). Reduced inhibin B in the follicular phase of the
menstrual cycle was an early event in the MT in the Melbourne
Women’s Health Cohort study (40). The rise in FSH that ac-
companies the loss of inhibin B has been associated with short-
ened follicular phases and abnormal follicle development com-
pared with younger reproductive-aged women (41, 42). Taken
together, these observations favor the hypothesis that folliculo-
genesis is less effective with reproductive aging, and this leads to
luteal dysfunction and anovulation. Decreasing Pdg was associ-
ated with progression of menopausal status, as defined by self-
reported cycle patterns at the annual interview.
Anovulatory cycles not associated with a bleeding episode
were modestly associated with subsequent progress from pre-
FIG. 3. Adjusted mean whole-cycle urinary reproductive hormones (with CI) by age and elapsed years since baseline, ovulatory cycles only. The P value
for each relationship is shown above the trio of bars to which it refers.
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menopause to early menopause and very strongly associated
with transition from early to late perimenopausal status. In con-
trast, anovulatory cycles with a bleeding episode were not sig-
nificantly related to progress to the early or late stages of the
transition and were associated with near-normal E1c excretion.
On the other hand, anovulatory/nonbleeding collections were
relatively hypoestrogenic. Our data collection paradigm did not
allow us to observe beyond 50 d of collection; we therefore can-
not knowwhether or not folliculogeneis and ovulation occurred
in some of the apparently anovulatory/nonbleeding collections
after 50 d. Our data suggest that the progression of cycle types
associated with transition to menopause begins with ovulatory
changing to anovulatory/nonbleeding cycles and then to meno-
pause. Anovulatory cycles ending with a bleed were not related
to the transit time. It remains to be seen if the appearance of
anovulatory/nonbleeding collections is more closely associated
with time to theFMP.The relationshipof anovulatory/nonbleed-
ing cycles to both low and high early follicular-phase serum es-
tradiol, as reported by us previously as a strong predictor of the
FMP (28), argues that progress to an anovulatory/nonbleeding
cycle typewill prove tobepredictive of a shorter time to theFMP.
A similar linkage of high estrogen to a more rapid transit to
menopause has been observed by others in smaller cross-sec-
tional studies (31, 36). In SWAN, which collects blood in the
early follicular phase when women are cycling regularly and
randomly when women become irregular, the higher estrogen
levels may be due in part to the change in timing of the blood
collection.
Manyoutcomes in SWANhave been associatedwithmarkers
of themetabolic syndrome (9, 43, 44). In this analysis, other than
a borderline association of-cell function to ovulatory status, no
direct relationship was observed between cycle types and meta-
bolicmarkers. However, a small number of womenwho became
menopausal and a larger proportion of women who did not
continue to complete DHS collections beyond the first year did
not contribute data to this study. The attrition of data is biased
towardwomenwith amore advancedmenopausal status, a state
that would be likely to be associated with worsening glucose
metabolism. Therefore, a systematic underestimation of the
amount of metabolic challenge incurred as women traverse the
menopause may have accounted for our lack of statistically sig-
nificant findings.
FIG. 4. Adjusted mean whole-cycle urinary reproductive hormones (with CI) by ethnicity and metabolic syndrome, ovulatory cycles only. Asterisks above
each pair of bars indicate statistical significance for metabolic syndrome-related differences. *, P  0.05.
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Ontheotherhand, obesityper sewas strongly associatedwith
an increased likelihood of anovulation ending in bleeding vs.
having an ovulatory cycle and has been previously shown to be
strongly related to reduced whole-cycle (8, 45, 46) and early
follicular-phase (10, 11) hormones. A high BMI has also been
shown to be associated with a higher proportion of involuntary
infertility (19, 47). It is likely that increasing BMI modulates
reproductive hormones through the transition, perhaps by in-
creasing the relative risk for anovulation. Obesity is a metabolic
stressor that is also highly concordant with waist circumference,
a key component of the definition of metabolic syndrome. Anal-
yses of metabolic markers did not adjust for BMI for this reason.
Despite this lack of adjustment, a significant relationship was
still not evident. It therefore seems likely that BMI influences
reproductive hormones in a manner apart from its relationship
to the metabolic syndrome.
We have also observed differences in daily hormones by eth-
nicity in SWAN(10, 11). The lowerLHandE1cobserved inboth
Chinese and Japanesewomenaswell as the lowerE1c inAfrican-
American women is not readily explainable on the basis of
known characteristics of the sample. For example, if race/eth-
nicity interacted with BMI, accounting for these differences, one
would not expect both the leaner groups (Chinese and Japanese)
to bemore similar to each other than to the group in SWANwith
the highest BMI (African-Americans). Lower circulating estrone
and estradiol have been previously reported in Japanese com-
paredwithAmericanwomenandattributed to altered enzymatic
metabolism (20). It is possible that these mechanisms are shared
among both Asian and African-American ethnicities. However,
such a relationship cannot explain the ethnic differences in the
gonadotropin patterns we observed.
Educational levelwas related toovulatory status in a complex
way. Greater than high school education was associated with
anovulatory cycles ending with a bleed, but by H3, women with
less thanahigh school educationweremore likely tohave anovu-
latory/nonbleeding collections. It is unclear how social factors
such as educational level might be causally related to ovulatory
status, but such factors dohave abearing onother characteristics
of participants, such as BMI, which in turn appear to be strongly
related to ovulatory status. Alternatively, such apparent rela-
tionships may simply be spurious and should be verified in other
studies.
Our study has some weaknesses that should be acknowl-
edged. Attrition from our baseline DHS sample was not random
and included more women with a variety of characteristics as-
TABLE 3. Adjusted ORs for baseline glucose metabolism indicators from multivariate random-effects logistic regression for
anovulatory cycles ending with and without a bleed vs. ovulatory cycles, adjusting for all predictor variables in models in Table 2
Baseline glucose metabolism
indicatora
Anovulatory cycles ending with
a bleed vs. ovulatory cycles (1666
observations/732 women)
Anovulatory/nonbleeding
collections vs. ovulatory cycles
(1758 observations/754 women)
Adjusted OR
(CI)
P
value
Adjusted OR
(CI)
P
value
Log glucose 1.11 (0.85–1.44) 0.44 0.84 (0.63–1.10) 0.20
Log insulin 1.22 (0.90–1.65) 0.20 1.18 (0.87–1.61) 0.28
Log -cell function 1.12 (0.84–1.49) 0.43 1.33 (0.99–1.78) 0.06
Log insulin resistance 1.23 (0.91–1.68) 0.18 1.12 (0.82–1.54) 0.47
Log insulin sensitivity 0.82 (0.61–1.11) 0.20 0.85 (0.62–1.16) 0.31
Metabolic syndrome 0.66 0.33
No Reference Reference
Yes 0.88 (0.51–1.55) 0.73 (0.39–1.37)
Diabetesb
No Reference 0.35 Reference 0.73
Yes 0.65 (0.26–1.61) 1.16 (0.50–2.71)
a For all predictors except metabolic syndrome, ORs were computed comparing the 75th percentile to the 25th percentile. Each glucose metabolism indicator is
included separately.
b These analyses include women with prevalent diabetes mellitus at baseline.
FIG. 5. Adjusted OR for anovulation by baseline serum estradiol. The
vertical line in the middle of the figure represents unity (OR  1). The OR
is shown as the middle of each horizontal line, with the outer limits
representing the lower and upper CI.
J Clin Endocrinol Metab, May 2008, 93(5):1711–1721 jcem.endojournals.org 1719
 at Med Schl Libr Univ of Massachusetts on April 20, 2010 jcem.endojournals.orgDownloaded from 
sociatedwith a shorter time to their FMP. Thus, our datamay be
biased toward detecting less change over time than would have
been detected had we been able to capture more cycles in the
longitudinal sample, thereby reducing our ability to detect true
changes over time. To compensate for the loss of cycles thatwere
expected to occur as women progressed farther through their
MT, we attempted to increase our ability to use data from
womenwhose collections did not begin or endwith a bleed. This
adjustment appeared to introduce minimal bias when analyses
were carried out with or without inclusion of these women’s
cycles. Urinary hormones, although useful for interpretation of
cyclepatterns, donotperfectly reflect circulating sex steroids and
gonadotropins. This is most true for E1c, whichmeasures amix-
ture of E1cs and reflects both serum estradiol and estrone. Be-
cause our women are still in the earlier stages of the MT, the
contribution of estrone to the overall pool of bioactive estrogen
is relatively minor; however, the molar quantity of estrone is
relatively high, and thus, urinary E1c is relatively less sensitive to
fluctuations in estradiol. This aspect of the assay makes it diffi-
cult to discern estradiol-related differences in E1c between
groups and over time.
In summary,wehave shown that daily reproductive hormone
assessments in urinary samples can provide valuable longitudi-
nal data that further elucidate the physiology of the MT. Both
declining luteal progesterone excretion in ovulatory cycles and
the appearance of long, anovulatory cycles (50 d) that do not
result in bleeding appear to herald progress through the MT.
Both lowandhigh early follicular-phase estradiol also appears to
herald progress through the transition. Anovulation with bleed-
ing intervals of fewer than 50 d does not appear to be associated
with progress through the transition but may be associated with
obesity. As SWAN accrues more women who have undergone
their FMP, the ability to form causal inferences should be
strengthened.
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